Trials / Completed
CompletedNCT04788472
Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL
Clinical Trial for the Efficacy and Safety of Sequential CD19 and CD22 CAR-T Therapy for Adult Patients with Newly Diagnosed Ph Chromosome Positive B-cell Acute Lymphoblastic Leukemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Clinical Trial for the Efficacy and Safety of Sequential CD19 and CD22 CAR-T Therapy for Adult Patients With Newly Diagnosed Ph Chromosome Positive B-cell Acute Lymphoblastic Leukemia
Detailed description
This study was designed as a prospective, open-label, single-center study. It aims to evaluate the efficacy and safety of CD19 CAR-T cells in combination with dasatinib for the treatment of newly diagnosed Ph-positive B-cell acute lymphoblastic leukemia in adult.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CAR-T cells targeting CD19 and CD22 | Each subject receives sequential CD19 and CD22 CAR-T cells by intravenous infusion |
Timeline
- Start date
- 2021-03-05
- Primary completion
- 2024-08-31
- Completion
- 2024-08-31
- First posted
- 2021-03-09
- Last updated
- 2024-10-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04788472. Inclusion in this directory is not an endorsement.